Many of the problems with current anti-tumour therapies stem from a lack of specificity for tumour as opposed to normal tissues. To address the problem of collateral toxicity during anti-tumour chemotherapy we have been developing a gene therapy approach to protect normal tissues from the toxic and potentially mutagenic effects of chemotherapeutic agents. As a paradigm for this we have been examining the potential of the DNA repair protein O 6 -alkylguanine-DNA-alkyltransferase (ATase) to confer genetic chemoprotection to the bone marrow. By transfer and expression of a mutant form of this protein, which is resistant to inactivation by the tumour sensitising agent O 
6
alkyguanine-DNA-alkyltransferase Systemic chemotherapy is an important and highly successful means of anti-tumour treatment. A plethora of drugs are used clinically either alone or, more usually, in combination to achieve tumour kill and remission from disease in patients. However, physicians using chemotherapeutic antitumour agents encounter a number of problems. Firstly, such agents seldom show specificity for tumour cells and their use is associated with acute toxicity in normal tissues, particularly those with a high proliferative index such as bone marrow, gut and lung. Indeed, toxicity to bone marrow (myelosuppression and/or thrombocytopenia) is often a major factor limiting the dose(s) of agent(s) that may be administered to a patient. However, although bone marrow toxicity may be the first dose-limiting toxicity encountered, toxicity to the gastrointestinal tract and lung are also important factors. In addition to acute toxicity, a number of agents are associated with late effects in normal tissues and these also impact on the doses and regimens that are employed by physicians. For example, the emergence of secondary (iatrogenic) leukaemia is associated with the use of O 6 -alkylating agents. 1 Similarly, a schedule-dependent incidence of secondary leukaemia is associated with the clinical use of etoposide. 2 A further confounding factor in anti-tumour treatment is the inherent or acquired resistance of some tumours to particular agents or classes of agents, often as a result of the expression of specific 'resistance factors' by tumour cells. A large number of such resistance factors have been identified (see Table 1 ) which confer resistance to many different agents. Examples include the MDR-1 trans-membrane pump, P-glycoprotein, which confers resistance to a wide range of drugs including the anthracyclins and epipodophyllotoxins, and the DNA repair protein O 6 -alkylguanine-DNA-alkyltransferase (ATase), which protects against the cytotoxic and genotoxic effects of the O 6 -alkylating agents. In order to overcome tumour insensitivity to treatment a number of inhibitors of resistance functions have been utilised. However, whilst these may be effective in reducing tumour resistance, their use may be associated with increased normal tissue toxicity. For example, the ATase pseudo-substrate O 6 -benzylguanine (O 6 -beG) is currently undergoing clinical trial as a tumour sensitiser. However, it is clear that its use exacerbates myelotoxicity due to O 6 -alkylating agents. 3, 4 In an attempt to confer protection to normal tissues, a number of groups have been investigating the potential for gene transfer of resistance functions to otherwise drugsensitive normal cells. 5 For example, MDR-1 gene transfer has been shown to confer protection against a wide range of drugs in in vitro experiments and in animal models of bone marrow protection. 6, 7 A number of clinical trials of bone marrow protection with MDR-1 have been initiated but have met with little success, due mostly to low levels of gene transfer and expression in patient bone marrow. 8, 9 We have been investigating the utility of ATase-based gene transfer to protect the bone marrow against the toxicity and clastogenicity of O 6 -alkylating agents. To do this we have engineered a mutant form of ATase (hATPA/GA) containing both a P 140 A and a G 156 A mutation, which jointly are predicted to alter access to the active site of ATase. 10 The hATPA/GA protein is extremely resistant to inactivation by the tumour sensitiser O In order to investigate the potential of hATPA/GA gene transfer to provide chemoprotection in vivo we have developed a mouse transplantation model (Figure 1) . 12 In this, female mice are transplanted with retrovirally transduced male bone marrow cells and allowed to reconstitute -beG a significant protection of the GM-CFC and CFU-S populations was observed. Thus, in control animals 13% and 10% survival of the GM-CFC and CFU-S populations was seen, respectively. In contrast, animals that expressed hATPA/GA as a consequence of retroviral gene transfer exhibited 33% GM-CFC survival and 38% CFU-S survival. A similar result was seen when animals were challenged with the imidotriazene mitozolomide. The survival of the GM-CFC and CFU-S compartments in control animals was 24% and 18%, respectively, whilst that in hATPA/GA mice was 44% and 37%, respectively.
In addition to assessing the outcome in the progenitor populations it is important to determine the effects of the chemoprotective gene on the response of the mature compartments to DNA damaging agents. We have been looking at the effects of temozolomide/O 6 -beG on the platelet compartment of mice, since thrombocytopenia is the primary dose-limiting toxicity encountered with this agent combination. Thus, both control and hATPA/GA animals received three sequential doses of 100 mg/kg temozolomide, in combination with 30 mg/kg O 6 -beG, with 2 days separating each dose (Figure 2) . One week following treatment, platelet numbers in control mice had dropped dramatically and continued to do so over the subsequent week with a small recovery in numbers evident by 3 weeks post treatment. In sharp contrast, however, hATPA/GA mice exhibited only a minor drop in platelet numbers, which quickly recovered to normal levels. We are currently investigating the effects of repeat dosing of animals following recovery of platelet numbers, with a view to determining the potential for dose escalation in chemoprotected patients, as well as the long-term effects on the haemopoietic potential and clonality of the bone marrow.
In addition to the toxic effects on bone marrow, and subsequent effects in the mature cell populations, the use of O 6 -alkylating agents clinically is associated with the induction of iatrogenic leukaemias. This is undoubtedly a reflection of the DNA damaging nature of these agents and results from occult damage in cells that survive drug exposure. In our earlier experiments with RJKO cells, we tested the hypothesis that expression of hATPA/GA in cells might lead to a reduction in the mutation frequency following exposure to O (Figure 3 ). Subsequent to this we have used the mouse bone marrow micronucleus (BMMN) assay as a measure of genotoxic (not cytotoxic) damage in cells. This assay detects clastogenic damage that manifests in the erythroid compartment as the production of a micronucleus, which is not extruded during erythroid maturation. The frequency of micronucleated polychromatic erythrocytes is used as a measure of the clastogenic potential of drugs and drug combinations, and the BMMN assay scores positive with every known human carcinogen and leukaemogen. 13 Using our mouse model described above we have shown significant protection of bone marrow by hATPA/GA against the clastogenic affects of a number of O 6 -alkylating agents, including temozolomide, mitozolomide, BCNU, fotemustine and streptozotocin, in combination with O 6 -beG. 12, 14 These data strongly suggest that it may be possible to protect bone marrow not only against the cytotoxic effects of O 6 -beG/O 6 -alkylating agent combinations, but also against late effects such as leukaemogenesis.
Our data have prompted us to seek permission for a clinical trial of hATPA/GA gene transfer in patients undergoing treatment with temozolomide/O 6 -beG for melanoma and (paediatric) glioma. This should prove a good test of the potential of this approach. Meanwhile we are evaluating the potential for providing protection against the effects of multiple classes of agents, via the co-expression of two or more protective factors. We have constructed a dual function retrovirus expressing both MDR-1 and ATase and in preliminary experiments have demonstrated protection of K562 cells against the cytotoxic effects of such diverse agents as methynitrosourea, mitozolomide colchicine and doxorubicin, both alone and in combination. 15 This vector is now under assessment in our animal model. We are also investigating the potential for the protection of other important dose-limiting toxicities (such as gut and lung). To this end we have constructed adeno-associated virus (AAV) vectors expressing ATase and have used these to confer protection to epithelial cell lines. 16 These are now under study in an in vivo model of O 6 -beG/O 6 -alkylating agent-induced gut toxicity.
